177 related articles for article (PubMed ID: 10499629)
1. Gains of 1q21-q22 and 13q12-q14 are potential indicators for resistance to cisplatin-based chemotherapy in ovarian cancer patients.
Kudoh K; Takano M; Koshikawa T; Hirai M; Yoshida S; Mano Y; Yamamoto K; Ishii K; Kita T; Kikuchi Y; Nagata I; Miwa M; Uchida K
Clin Cancer Res; 1999 Sep; 5(9):2526-31. PubMed ID: 10499629
[TBL] [Abstract][Full Text] [Related]
2. [Comparative genomic hybridization for analysis of chromosomal changes in cisplatin-resistant ovarian cancer].
Kudoh K; Takano M; Koshikawa T; Yoshida S; Hirai M; Kikuchi Y; Nagata I; Miwa M; Uchida K
Hum Cell; 2000 Sep; 13(3):109-16. PubMed ID: 11197772
[TBL] [Abstract][Full Text] [Related]
3. Analyses by comparative genomic hybridization of genes relating with cisplatin-resistance in ovarian cancer.
Takano M; Kudo K; Goto T; Yamamoto K; Kita T; Kikuchi Y
Hum Cell; 2001 Dec; 14(4):267-71. PubMed ID: 11925927
[TBL] [Abstract][Full Text] [Related]
4. Amplicon profiling reveals cytoplasmic overexpression of MUC1 protein as an indicator of resistance to platinum-based chemotherapy in patients with ovarian cancer.
Takano M; Fujii K; Kita T; Kikuchi Y; Uchida K
Oncol Rep; 2004 Dec; 12(6):1177-82. PubMed ID: 15547734
[TBL] [Abstract][Full Text] [Related]
5. Comparative genomic hybridization analysis of chromosomal changes occurring during development of acquired resistance to cisplatin in human ovarian carcinoma cells.
Wasenius VM; Jekunen A; Monni O; Joensuu H; Aebi S; Howell SB; Knuutila S
Genes Chromosomes Cancer; 1997 Apr; 18(4):286-91. PubMed ID: 9087568
[TBL] [Abstract][Full Text] [Related]
6. [The mechanism of cisplatin-resistance in ovarian cancer].
Kikuchi Y
Hum Cell; 2001 Jun; 14(2):115-33. PubMed ID: 11552292
[TBL] [Abstract][Full Text] [Related]
7. High-resolution genomic profiling of carboplatin resistance in early-stage epithelial ovarian carcinoma.
Osterberg L; Levan K; Partheen K; Staaf J; Sundfeldt K; Horvath G
Cytogenet Genome Res; 2009; 125(1):8-18. PubMed ID: 19617691
[TBL] [Abstract][Full Text] [Related]
8. High definition cytogenetics and oligonucleotide aCGH analyses of cisplatin-resistant ovarian cancer cells.
Prasad M; Bernardini M; Tsalenko A; Marrano P; Paderova J; Lee CH; Ben-Dor A; Barrett MT; Squire JA
Genes Chromosomes Cancer; 2008 May; 47(5):427-36. PubMed ID: 18273836
[TBL] [Abstract][Full Text] [Related]
9. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients.
Chen YJ; Yuan CC; Chow KC; Wang PH; Lai CR; Yen MS; Wang LS
Gynecol Oncol; 2005 Apr; 97(1):110-7. PubMed ID: 15790446
[TBL] [Abstract][Full Text] [Related]
11. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
[TBL] [Abstract][Full Text] [Related]
12. 1p31, 7q21 and 18q21 chromosomal aberrations and candidate genes in acquired vinblastine resistance of human cervical carcinoma KB cells.
Wang J; Tai LS; Tzang CH; Fong WF; Guan XY; Yang M
Oncol Rep; 2008 May; 19(5):1155-64. PubMed ID: 18425371
[TBL] [Abstract][Full Text] [Related]
13. Analysis of chromosomal changes in serous ovarian carcinoma using high-resolution array comparative genomic hybridization: Potential predictive markers of chemoresistant disease.
Kim SW; Kim JW; Kim YT; Kim JH; Kim S; Yoon BS; Nam EJ; Kim HY
Genes Chromosomes Cancer; 2007 Jan; 46(1):1-9. PubMed ID: 17044060
[TBL] [Abstract][Full Text] [Related]
14. Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients.
Song J; Shih IeM; Salani R; Chan DW; Zhang Z
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6842-9. PubMed ID: 17982121
[TBL] [Abstract][Full Text] [Related]
15. Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors.
Cullen KJ; Newkirk KA; Schumaker LM; Aldosari N; Rone JD; Haddad BR
Cancer Res; 2003 Dec; 63(23):8097-102. PubMed ID: 14678959
[TBL] [Abstract][Full Text] [Related]
16. Nucleotide excision repair pathway review I: implications in ovarian cancer and platinum sensitivity.
Saldivar JS; Wu X; Follen M; Gershenson D
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S56-71. PubMed ID: 17884153
[TBL] [Abstract][Full Text] [Related]
17. [Mechanisms of drug resistance in human ovarian carcinoma studied by comparative genomic hybridization].
Ying HC; Zhang SL; Jiang T; Ouyang L; Lü J
Zhonghua Yi Xue Za Zhi; 2007 Apr; 87(15):1009-12. PubMed ID: 17672960
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide.
Ohie S; Udagawa Y; Kozu A; Komuro Y; Aoki D; Nozawa S; Moossa AR; Hoffman RM
Anticancer Res; 2000; 20(3B):2049-54. PubMed ID: 10928150
[TBL] [Abstract][Full Text] [Related]
19. Cytogenetic analysis of carboplatin resistance in early-stage epithelial ovarian carcinoma.
Osterberg L; Levan K; Partheen K; Helou K; Horvath G
Cancer Genet Cytogenet; 2005 Dec; 163(2):144-50. PubMed ID: 16337857
[TBL] [Abstract][Full Text] [Related]
20. Expression of the cisplatin resistance phenotype in a human ovarian carcinoma cell line segregates with chromosomes 11 and 16.
Mirakhur B; Parekh HK; Simpkins H
Cancer Res; 1996 May; 56(10):2256-62. PubMed ID: 8625294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]